Galactorrhea Development During Isotretinoin Treatment: Is It a Novel Side Effect?

Öz

Isotretinoin is a synthetic retinoic acid used in the treatment of resistant acne. Although isotretinoin is very effective in the treatment of acne vulgaris, it has been associated with various adverse effects. An 18-year-old female patient with isotretinoin treatment at the dose of 40 mg/day due to acne vulgaris, the complaint of milk discharge was evaluated as galactorrhea in the second month of treatment. It was learned that she had no other illness and did not take any medication. Laboratory and imaging studies were found to be normal examined for etiological cause. We found only one case reports of galactorrhea associated with the use of isotretinoin in the literature. This article presents a case study of galactorrhea without hyperprolactinemia in a woman being treated with isotretinoin.

Anahtar Kelimeler

• Isotretinoin
• galactorrhea
• side effect
• association

İzotretinoin Tedavisi Sırasında Galaktore Gelişimi: Yeni Bir Yan Etki mi?

Öz

İzotretinoin şiddetli akne tedavisinde kullanılan sentetik bir retinoik asittir. Akne tedavisinde çok etkili olmasına karşın pek çok yan etkileri bulunmaktadır. Akne vulgaris nedeniyle, 40 mg/gün dozunda izotretinoin tedavisi başlanan, 18 yaşındaki kadın bir hastanın, tedavisinin ikinci ayında, sağ memesinden sütlü akıntı gelme şikayeti galaktore olarak değerlendirildi. Başka bir hastalığı ve herhangi bir ilaç kullanma öyküsü yoktu. Etiyolojik nedene yönelik yapılan incelemede laboratuvar ve görüntüleme tetkikleri normal bulundu. Literatürde izoretinoinle ilişkili sadece bir olgu bulunmaktadır. Bu makalede izotretinoin tedavisi sırasında ortaya çıkan hiperprolaktinemisiz galaktore olgusu sunulmaktadır.

Anahtar Kelimeler

• İsotretinoin
• galaktore
• yan etki
• birliktelik

Kaynakça

1. Bener F, Güngör E, Şeneş M, Karakaş A, Ekşioğlu M. Sistemik izotretinoin tedavisinin serum hormonları ve menstrüel siklus üzerine etkileri. Ankara Eğt Arş Hast Derg. 2018;51(2):145-149.
2. Eckhoff C, Nau H. Identification and quantitation of all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. Lipid Res. 1990;31(8):1445-54.
3. Larsen GK. Iatrogenic breast discharge with isotretinoin. Arch Dermatol. 1985;121(4):450-1.
4. Huang W, Molitch ME. Evaluation and Management of Galactorrhea. Am Fam Physician. 2012;85(11):1073-80.
5. Abha A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168-175.
6. Pena KS, Rosenfeld JA. Evaluation and Treatment of Galactorrhea. Am Fam Physician. 2001;63(9):1763-1771.
7. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry. 1994;151(9):1395-6.
8. Mahasuar R, Majhi P, Ravan JR. Euprolactinemic galactorrhea associated with use of imipramine and escitalopram in a postmenopausal woman. Gen Hosp Psychiatry. 2010;32(3):11-13.

9. Leung AK, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician. 2004;70(3):543-50.
10. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borelli E, et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science. 1998;279(5352):863-867.
11. O'Reilly KC, Trent S, Bailey SJ, Lane MA. 13-cis-Retinoic acid alters intracellular serotonin, increases 5-HT1A receptor, and serotonin reuptake transporter levels in vitro. Exp Biol Med. 2007;232(9):1195-203.
12. Kontaxakis VP, Skourides D, Ferentinos P, Havaki-Kontaxaki BJ, Papadimitriou GN. Isotretinoin and psychopathology: a review. Ann Gen Psychiatry. 2009;8:2.
13. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, et al. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res. 1995;55(19):4446-51.
14. Fukunaka K, Saito T, Wataba K, Ashihara K, Ito E, Kudo R. Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle. Mol Hum Reprod. 2001;7(5):437-446.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.